IGF1R and Ewing sarcoma: Pharmacological blockade of the IGF1R using mAbs or TKIs inhibited Ewing sarcoma cells proliferation, soft-agar growth, migration and inhibited downstream signalling, increased apoptosis, and blunted in vivo tumor growth [159,160,161,162].